🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

RecruitingPhase 4Ages 18 Years - anyAllOttawa Hospital Research Institute
NCT04642430 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be fatal. A stroke occurs when blood flow to the brain is blocked by a clot, depriving brain cells of oxygen. In people with atrial fibrillation, blood flow is sluggish in the top chambers of the heart, and blood clots can form there. When a piece of a clot breaks off, it can travel to the brain and cause a stroke. That's where blood thinners come in. Blood thinners, or anticoagulants, decrease the chances of blood clots forming in the heart, reducing the risk of stroke. Studies show that blood thinners are highly effective at reducing the risk of stroke by up to 95%. The conventional blood thinner is warfarin, take

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years old * Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian Cardiovascular Society guidelines Exclusion Criteria: * Creatinine clearance =\<15 ml/min calculated using the Cockcroft-Gault formula * Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to: * active bleeding * history of mechanical valve * other indication for anticoagulation (e.g. mechanical valves, venous thrombosis) * dual antiplatelet agent use * known liver disease with coagulopathy * use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein) * pregnancy or breastfeeding
💊

What it tests

  • Apixaban
  • Rivaroxaban
📍

Where

8 sites
Victoria Cardiac Arrhythmia Trials
Victoria, Canada
QEII Health Science Centre
Halifax, Canada
Kingston General Hospital
Kingston, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
University Ottawa Heart Institute
Ottawa, Canada
CISSS de l'Outaouais
Gatineau, Canada
CHU de Quebec - Université Laval
Laval, Canada
Ciusss Nim
Montreal, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy